Study on SGLT2i therapy after islet transplantation
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether a diabetes medication called empagliflozin (an SGLT2 inhibitor) can help people who have had an islet transplant (TPIAT) better manage their blood sugar. It aims to see if it improves how well the transplanted islets work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- At least 1 year has passed since your islet transplant (TPIAT).
- Your pancreas still makes some insulin (stimulated C-peptide at least 0.6 ng/mL) and you need only a small amount of insulin (≤0.25 units per kg each day) or you have high blood sugar (HbA1c above 6.5%) without insulin.
- Your diabetes treatment (insulin pump or multiple daily injections) has been stable for at least 8 weeks, with no big changes in dose.
- You are willing to wear a continuous glucose monitor, record insulin doses, and come to the University of Minnesota for 3 study visits over about 6 months.
- You have not used any diabetes medications other than insulin in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.